6998 — Edding Genor group Share News
0.000.00%
Last trade - 00:00- HK$3.20bn
- HK$3.52bn
- CNY2.49bn
Brief: Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HY
Brief: Jhbp Cy Disposal Of Equity Interest In Candid Therapeutics
Edding Genor climbs on approval of clinical trial of cancer drug in China
Brief: JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA
Brief: Edding Genor Says CEO Initiates Plan To Purchase Additional Shares In Open Market
Brief: Edding Genor Posts Net Profit Increased To Rmb399.3 Million In 2025
Brief: Genor Biopharma Says NMPA Granted New Drug Application Approval For Lerociclib (Gb491)
Brief: Genor Biopharma, Its Unit & Edding Group Entered Into Merger Agreement
Brief: Genor Biopharma Says Guo Feng Tendered His Resignation As Chairman
Brief: Genor Biopharma Holdings Posts H1 Net Income Attributable RMB -125.7 Million
Brief: Genor Biopharma Says On 2 Aug, Co Entered License Deal And Stock Purchase Deal With TRC 2004
Brief: Jhbp Cy Says NMPA Accepts New Drug Application For Gb491 (Lerociclib)
Brief: Genor Biopharma Posts HY Loss Attributable RMB274.6 Million
Brief: JHBP CY Notified By NMPA That New Product Application Approval Of Geptanolimab Was Not Granted
Brief: Genor Biopharma Posts FY Loss Of RMB730.4 Million
Brief: Jhbp Cy Says China's Nmpa Accepted New Drug Application For Gb491 (Lerociclib) With Fluvestran
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Brief: Genor Biopharma Says Maintains Accounts At Silicon Valley Bank With Minimal Cash Balance
Brief: Jhbp Cy To Launch Of Phase I/II Clinical Trial Of Gb261 In China